ZA200508985B - Inhibition of apotosis process and improvement of cell performance - Google Patents

Inhibition of apotosis process and improvement of cell performance

Info

Publication number
ZA200508985B
ZA200508985B ZA200508985A ZA200508985A ZA200508985B ZA 200508985 B ZA200508985 B ZA 200508985B ZA 200508985 A ZA200508985 A ZA 200508985A ZA 200508985 A ZA200508985 A ZA 200508985A ZA 200508985 B ZA200508985 B ZA 200508985B
Authority
ZA
South Africa
Prior art keywords
cell
apotosis
inhibition
improvement
cell performance
Prior art date
Application number
ZA200508985A
Other languages
English (en)
Inventor
Mithcell Reff
Figueroa Bruno Jr
Marie Hardwick
Michael J Betenbaugh
Eric Ailor
Original Assignee
Biogen Idec Inc
John Hopskins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc, John Hopskins University filed Critical Biogen Idec Inc
Publication of ZA200508985B publication Critical patent/ZA200508985B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ZA200508985A 2001-07-10 2002-07-10 Inhibition of apotosis process and improvement of cell performance ZA200508985B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30381301P 2001-07-10 2001-07-10

Publications (1)

Publication Number Publication Date
ZA200508985B true ZA200508985B (en) 2006-07-26

Family

ID=23173824

Family Applications (2)

Application Number Title Priority Date Filing Date
ZA200508985A ZA200508985B (en) 2001-07-10 2002-07-10 Inhibition of apotosis process and improvement of cell performance
ZA200400137A ZA200400137B (en) 2001-07-10 2004-01-08 Inhibition of apoptosis process and improvement of cell performance

Family Applications After (1)

Application Number Title Priority Date Filing Date
ZA200400137A ZA200400137B (en) 2001-07-10 2004-01-08 Inhibition of apoptosis process and improvement of cell performance

Country Status (13)

Country Link
US (1) US7604989B2 (de)
EP (1) EP1414948B1 (de)
JP (2) JP4435563B2 (de)
KR (1) KR20040044433A (de)
CN (1) CN1526011A (de)
AT (1) ATE443131T1 (de)
AU (1) AU2002315534B2 (de)
CA (1) CA2452005C (de)
DE (1) DE60233738D1 (de)
MX (1) MXPA04000281A (de)
NO (1) NO20040101L (de)
WO (1) WO2003006607A2 (de)
ZA (2) ZA200508985B (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7812148B2 (en) 2001-04-05 2010-10-12 Millipore Corporation Vectors comprising CpG islands without position effect varigation and having increased expression
KR100454016B1 (ko) * 2002-01-05 2004-10-26 한국과학기술원 항예정사 유전자로 형질전환되고 ｄｈｆｒ 유전자가결핍된 신규한 ｃｈｏ 세포주, 그의 제조 방법 및 상기형질전환된 ｃｈｏ 숙주 세포를 이용한 목적단백질의 생산방법
US9057079B2 (en) 2003-02-01 2015-06-16 Emd Millipore Corporation Expression elements
ATE465245T1 (de) * 2003-10-24 2010-05-15 Chemo Sero Therapeut Res Inst Neue rekombinante tierzellen mit hoher proteinproduktion, verfahren zur konstruktion davon sowie verfahren zur massenproduktion von protein unter verwendung davon
WO2005065348A2 (en) 2003-12-31 2005-07-21 Kalobios, Inc. Transactivation system for mammalian cells
US7537930B2 (en) 2004-07-23 2009-05-26 Immunomedics, Inc. Mammalian cell lines for increasing longevity and protein yield from a cell culture
US7531327B2 (en) * 2004-07-23 2009-05-12 Immunomedics, Inc. Methods and compositions for increasing longevity and protein yield from a cell culture
AU2005333513B2 (en) * 2004-07-23 2011-06-02 Immunomedics, Inc. Methods and compositions for increasing longevity and protein yield from a cell culture
US7608425B2 (en) * 2004-07-23 2009-10-27 Immunomedics, Inc. Methods for protein expression in mammalian cells in serum-free medium
WO2007015691A2 (en) * 2004-07-23 2007-02-08 Immunomedics, Inc. Methods and compositions for increasing longevity and protein yield from a cell culture
GB0509965D0 (en) 2005-05-17 2005-06-22 Ml Lab Plc Improved expression elements
JP4977691B2 (ja) * 2006-04-13 2012-07-18 中外製薬株式会社 タウリントランスポーター遺伝子
US20100167396A1 (en) * 2006-04-21 2010-07-01 Bayer Healthcare Llc Application of Anti-Apoptotic Gene Expression in Mammalian Cells for Perfusion Culture
EP2118270A2 (de) * 2007-01-08 2009-11-18 Millipore Corporation Zellkulturverfahren für die produktion rekombinanter proteine bei verminderter konzentration von einem oder mehreren kontaminanten
EP2300600B1 (de) 2008-06-13 2015-09-30 Janssen Biotech, Inc. Verfahren zur verbesserung von lebensfähigkeit und produktivität bei der zellkultur
US20130065312A1 (en) * 2009-11-03 2013-03-14 The Johns Hopkins University Method and composition for generating programmed cell death resistant algal cells
HUP1000243A2 (en) 2010-05-06 2012-01-30 Avidin Kft 8-hidroxy-quinoline derivatives
KR20200002050A (ko) 2018-06-28 2020-01-08 삼성디스플레이 주식회사 유기 발광 표시 장치

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136310A (en) 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
DE669986T1 (de) 1992-11-13 1996-10-10 Idec Pharma Corp Völlig unfunktionelle konsensus-kozak-sequenzen zur säugetier-exprimierung.
US5565491A (en) * 1994-01-31 1996-10-15 Bristol-Myers Squibb Company Use of phosphotyrosine phospatase inhibitors for controlling cellular proliferation
US5550050A (en) 1994-04-15 1996-08-27 Cytotherapeutics, Inc. Method for implanting encapsulated cells in a host
US5811524A (en) 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
US6001358A (en) 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
US6087129A (en) 1996-01-19 2000-07-11 Betagene, Inc. Recombinant expression of proteins from secretory cell lines
US5897992A (en) 1996-09-27 1999-04-27 Cold Spring Harbor Laboratory Cell-free assay using oncogene-induced apoptosis in drug-resistant cells
US6011138A (en) 1997-02-20 2000-01-04 Idec Pharmaceuticals Corporation Gamma-1 anti-human CD23 monoclonal antibodies
US5969102A (en) * 1997-03-03 1999-10-19 St. Jude Children's Research Hospital Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof
US5830698A (en) 1997-03-14 1998-11-03 Idec Pharmaceuticals Corporation Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same
WO2000008057A2 (en) 1998-08-07 2000-02-17 Immunex Corporation Molecules designated b7l-1
AU760466B2 (en) 1999-02-26 2003-05-15 Johns Hopkins University, The A novel inhibitor of programmed cell death
US6140118A (en) 1999-08-11 2000-10-31 Wisconsin Alumni Research Foundation Avian blastodermal cell lines
WO2001023592A2 (en) 1999-09-27 2001-04-05 Genentech, Inc. Methods for making recombinant proteins using apoptosis inhibitors
WO2001034149A1 (en) * 1999-11-12 2001-05-17 Merck & Co., Inc. Diaryl piperidyl pyrrole derivatives as antiprotozoal agents
KR100454016B1 (ko) 2002-01-05 2004-10-26 한국과학기술원 항예정사 유전자로 형질전환되고 ｄｈｆｒ 유전자가결핍된 신규한 ｃｈｏ 세포주, 그의 제조 방법 및 상기형질전환된 ｃｈｏ 숙주 세포를 이용한 목적단백질의 생산방법
EP1348758A1 (de) 2002-03-28 2003-10-01 Boehringer Ingelheim Pharma GmbH & Co.KG Wirtszellen mit verbessertem Überleben und Verfahren zur Herstellung von diesen Zellen

Also Published As

Publication number Publication date
CN1526011A (zh) 2004-09-01
WO2003006607A9 (en) 2003-04-10
EP1414948A4 (de) 2006-06-21
NO20040101L (no) 2004-03-09
KR20040044433A (ko) 2004-05-28
JP2009118851A (ja) 2009-06-04
JP4435563B2 (ja) 2010-03-17
JP2005525782A (ja) 2005-09-02
EP1414948A2 (de) 2004-05-06
US20030064510A1 (en) 2003-04-03
US7604989B2 (en) 2009-10-20
ZA200400137B (en) 2006-06-28
MXPA04000281A (es) 2004-07-23
WO2003006607A2 (en) 2003-01-23
CA2452005C (en) 2011-03-15
CA2452005A1 (en) 2003-01-23
DE60233738D1 (de) 2009-10-29
AU2002315534B2 (en) 2008-05-22
EP1414948B1 (de) 2009-09-16
WO2003006607A3 (en) 2003-07-31
ATE443131T1 (de) 2009-10-15

Similar Documents

Publication Publication Date Title
ZA200508985B (en) Inhibition of apotosis process and improvement of cell performance
YU40402A (sh) 4-pirimidinil-n-acil-l-fenilalanini
EP1332772A3 (de) Zusammensetzungen gegen Schuppen und Jukreiz, die ein Kältegefühl erzeugendes Material und einen Kältegefühl-Verstärker enthalten
SG170082A1 (en) Methods for regulating inflammatory mediators and peptides useful therein
EP1483281A4 (de) Verfahren zur herstellung interferierender rna-moleküle in säugetierzellen und therapeutische anwendungen solcher moleküle
CA2219081A1 (en) Angiostatin fragments and aggregate angiostatin and methods of use
PL331082A1 (en) Method of changing hair growth rate and hair pigmentation by apoptosis induced in hair papillas and composition therefor
ES2164653T3 (es) Procedimiento para producir heterociclos polihidroxilicos que contienen nitrogeno n-sustituidos.
AU3052799A (en) Pharmaceutical compositions comprising erythropoietin for treatment of cancer
MXPA02006116A (es) Actividad somnogenica de una bacteria acido lactica no-patogena.
PL335640A1 (en) Deep-frozen article of food
MXPA03007713A (es) Metodos para elaborar un oxido de metal de niobio.
WO2003099201A3 (en) Compositions and methods of use for a fibroblast growth factor
WO2003066814A3 (en) Peptide-dependent upregulation of telomerase expression
NZ515531A (en) Substituted 3-pyridyl-4-arylpyrroles, and related therapeutic and prophylactic methods
AU4300400A (en) Cereal product
NZ333412A (en) Plant proteins treated to reduce isoflavones, manganese and nucleotides and nutritional products made therefrom
WO2001044443A3 (en) Cytochrome p450rai-2 and related proteins
WO2003082900A3 (en) Self-assembling-peptide-based structures and processes for controlling the self-assembly of such structures
ES2032354B1 (es) Procedimiento para la fabricacion de papillas a base de cereales y papillas obtenidas con dicho procedimiento.
WO2005058939A3 (en) Methods and compositions for inhibition of bcl6 repression
CA102062S (en) Bun for hamburgers
YU72603A (sh) Proizvodnja i izdvajanje indolokarbazol glikozida
WO2002068668A3 (en) Compositions and methods for production cell culture
WO1998034602A3 (en) Mediation of cytokines by melanin